Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2021

View Archived Issues

Zeolitic imidazolate frameworks for sustained checkpoint inhibitor release in cancer immunotherapy

Preclinical results of an ACE2-interacting domain of SARS-CoV-2 peptide for COVID-19 treatment

Mucolipidosis type II AAV9 gene therapy demonstrates safety in wild-type mice

Interim phase I/II data show safety and systemic efficacy of RGX-121 in patients with MPS II

Sunshine Lake Pharma discovers teixobactin analogues

Preliminary phase II data for eganelisib plus nivolumab in advanced urothelial carcinoma

SIG-018 ameliorates symptoms of MPS II in preclinical models

New dihydroceramide desaturase inhibitors presented by Cincera Therapeutics

Dana-Farber Cancer Institute describes new CDK7/cyclin H inhibitors

New E-NPP 2 inhibitors identified at Boehringer Ingelheim

BeiGene patents MAP4K1 inhibitors

One-dose immunogenicity of BNT-162b2 vaccine among different groups of Israeli healthcare workers

Orchard Therapeutics reports data from trial of OTL-201 in MPS type III A

Multiorgan organoid gives developmental insights

First phase III data presented for nivolumab in patients with high-risk MIUC under radical surgery

FDA places partial clinical hold on atuzaginstat

Neuren reports phase I data on NNZ-2591 and plans to expand development into Prader-Willi syndrome

TLX-591-CDx for prostate cancer imaging receives first E.U. approval in Czech Republic

WHO lists two versions of AstraZeneca/Oxford COVID-19 vaccine for emergency use

Valbiotis gains French clearance to begin phase II study of TOTUM-070 to reduce LDL-cholesterol

InteRNA initiates first-in-human study of INT-1B3 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.